PMID- 22030896
OWN - NLM
STAT- MEDLINE
DCOM- 20120702
LR  - 20211203
IS  - 1533-4023 (Electronic)
IS  - 0160-2446 (Linking)
VI  - 59
IP  - 3
DP  - 2012 Mar
TI  - No significant effect of ginkgo biloba special extract EGb 761 in the treatment 
      of primary Raynaud phenomenon: a randomized controlled trial.
PG  - 215-21
LID - 10.1097/FJC.0b013e31823c0bed [doi]
AB  - BACKGROUND: Medicinal treatment of vasospastic Raynaud phenomenon is limited to 
      primarily vasodilator medicines. OBJECTIVE: To explore the possible beneficial 
      effects and tolerability of 120 mg two times a day of Ginkgo Biloba special 
      extract EGb 761 in patients suffering from Raynaud disease (RD) (primary Raynaud 
      phenomenon). METHODS: In a placebo-controlled, double-blind, pilot study, 41 
      patients with RD were randomized to either the active treatment group (EGb 761, n 
      = 21) or placebo group for 10 weeks, after an initial 2-week run-in phase. The 
      primary efficacy variables were self-reported changes of the frequency, duration, 
      and severity of vasospastic attacks between the placebo-controlled run-in phase 
      and the end of the study. RESULTS: Most of the patients were female, and both 
      groups were perfectly matched with respect to demographic characteristics. The 
      frequency of daily attacks reduced from 3.6 +/- 2.3 to 2.4 +/- 2.6 (-33%) in the EGb 
      761 group and from 2.9 +/- 2.0 to 2.0 +/- 1.8 (-31%) in the placebo group with no 
      significant difference according to the ordinary least squares test (P = 0.3564). 
      Furthermore, no significant differences were found with respect to the duration 
      and severity of vasospastic attacks between the EGb 761 and placebo groups (P = 
      0.4392 and P = 0.7187, respectively). In all, 17 adverse events (AEs) were 
      reported, 6 AEs from 5 patients in the EGb 761 group and 11 AEs from 8 patients 
      in the placebo group. Serious AEs did not occur. CONCLUSION: EGb 761 treatment 
      showed an excellent safety profile in patients with RD but could not demonstrate 
      a statistically significant reduction in clinically relevant symptoms compared 
      with placebo.
FAU - Bredie, Sebastian J H
AU  - Bredie SJ
AD  - Department of General Internal Medicine, Radboud University Nijmegen Medical 
      Centre, Nijmegen, the Netherlands. s.bredie@aig.umcn.nl
FAU - Jong, Miek C
AU  - Jong MC
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Cardiovasc Pharmacol
JT  - Journal of cardiovascular pharmacology
JID - 7902492
RN  - 0 (Plant Extracts)
RN  - 19FUJ2C58T (Ginkgo biloba extract)
SB  - IM
MH  - Adult
MH  - Double-Blind Method
MH  - Female
MH  - Ginkgo biloba
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Pilot Projects
MH  - Plant Extracts/adverse effects/*pharmacology
MH  - Raynaud Disease/*drug therapy/physiopathology
MH  - Severity of Illness Index
MH  - Time Factors
MH  - Treatment Outcome
MH  - *Vasoconstriction
EDAT- 2011/10/28 06:00
MHDA- 2012/07/03 06:00
CRDT- 2011/10/28 06:00
PHST- 2011/10/28 06:00 [entrez]
PHST- 2011/10/28 06:00 [pubmed]
PHST- 2012/07/03 06:00 [medline]
AID - 10.1097/FJC.0b013e31823c0bed [doi]
PST - ppublish
SO  - J Cardiovasc Pharmacol. 2012 Mar;59(3):215-21. doi: 10.1097/FJC.0b013e31823c0bed.